{"id":8913,"date":"2025-12-07T23:02:39","date_gmt":"2025-12-07T23:02:39","guid":{"rendered":"https:\/\/mailitics.com\/index.php\/2025\/12\/07\/gilead-arcellx-multiple-myeloma-treatment-anito-cel-promising-data-ash\/"},"modified":"2025-12-07T23:02:39","modified_gmt":"2025-12-07T23:02:39","slug":"gilead-arcellx-multiple-myeloma-treatment-anito-cel-promising-data-ash","status":"publish","type":"post","link":"https:\/\/mailitics.com\/index.php\/2025\/12\/07\/gilead-arcellx-multiple-myeloma-treatment-anito-cel-promising-data-ash\/","title":{"rendered":"STAT+: New data from Gilead, Arcellx multiple myeloma CAR-T suggest benefit over rival treatment"},"content":{"rendered":"

STAT+: New data from Gilead, Arcellx multiple myeloma CAR-T suggest benefit over rival treatment
\n \t

\n
<\/BR>
\n
\n \t

\n
<\/BR><\/p>\n

\n

ORLANDO, Fla. \u2014 With sales of its existing blood cancer CAR-T therapies weakening, Gilead Sciences needs anito-cel, its next CAR-T therapy for multiple myeloma \u2014 to succeed more than ever.\u00a0<\/p>\n

On Saturday at the annual meeting of the American Society of Hematology, the company and its partner Arcellx reported deepening and durable responses with no concerning safety issues in the latest analysis of a pivotal-stage clinical trial.<\/p>\n

Among 117 patients enrolled in the study, 96% showed a tumor response, with 74% of patients achieving complete remission, the companies said in a press release<\/a>.\u00a0<\/p>\n

Continue to STAT+ to read the full story\u2026<\/a><\/p>\n<\/div>\n

\t

\n
<\/BR>
\n Adam Feuerstein
\n \t

\n
<\/BR>
\nGo to statnews<\/a>
\n \t

\n
<\/BR><\/p>\n","protected":false},"excerpt":{"rendered":"

STAT+: New data from Gilead, Arcellx multiple myeloma CAR-T suggest benefit over rival treatment ORLANDO, Fla. \u2014 With sales of its existing blood cancer CAR-T therapies weakening, Gilead Sciences needs anito-cel, its next CAR-T therapy for multiple myeloma \u2014 to succeed more than ever.\u00a0 On Saturday at the annual meeting of the American Society of […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4374,2194,2154,2216,58,2159,3665,2152],"tags":[2150],"class_list":["post-8913","post","type-post","status-publish","format-standard","hentry","category-ash","category-biotech","category-biotechnology","category-breaking-news","category-business","category-cancer","category-gilead-sciences","category-stat","tag-statnews"],"_links":{"self":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts\/8913"}],"collection":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/comments?post=8913"}],"version-history":[{"count":0,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts\/8913\/revisions"}],"wp:attachment":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/media?parent=8913"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/categories?post=8913"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/tags?post=8913"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}